Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3000328 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose. |
| LY3000328 | EXPERIMENTAL | Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered orally |
| LY3000328 | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination
LY3000328 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its safety and tolerability. It is not approved by the FDA and remains in clinical development.
LY3000328 is being studied for use in healthy volunteers. The primary purpose of the clinical trial was to evaluate the safety and tolerability of the drug in healthy participants. It is not intended for a specific disease indication at this stage of development.
LY3000328 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company conducted a Phase 1 clinical trial to assess the drug's safety and tolerability in healthy participants.
LY3000328 is in Phase 1 clinical development. A Phase 1 trial has been completed, which involved 18 healthy participants. The study was randomized, double-blind, and placebo-controlled. The drug is investigational and has not been approved by regulatory authorities.
LY3000328 has been studied in one clinical trial, identified as NCT01515358. This was a Phase 1 study titled 'A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants.' The trial was completed and enrolled 18 participants in Singapore.
LY3000328 is the only name provided for this drug. No alternative names have been identified in the available information. It is a distinct investigational small molecule being developed by Eli Lilly and Company.